The European Commission has authorised Arexvy, the first vaccine to protect adults aged 60 and over, against lower respiratory tract disease caused by respiratory syncytial virus (RSV) The green light for the vaccine was particularly awaited in light of the increase in RSV infections in the EU last winter. In Europe, the RSC causes about 250,17 hospitalizations and 65,<> deaths each year in people aged <> and over.
The RSC is a common respiratory virus that usually causes mild, cold-like symptoms.